{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.3","value":"241.8"},{"groupId":"OG001","spread":"70.3","value":"250.8"},{"groupId":"OG002","spread":"61.0","value":"299.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"Cycle 1, n=29,17,19"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"52.6","value":"352.4"},{"groupId":"OG001","spread":"49.6","value":"372.0"},{"groupId":"OG002","spread":"91.7","value":"557.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Cycle 3, n=23,23,11"}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Blood samples were collected at designated timepoints. PK parameters of GSK2857916 total antibody were calculated using non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 2.5 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 39 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG000","title":"Main Study: GSK2857916 2.5 mg/kg (Frozen Liquid)"},{"description":"Participants were administered frozen liquid (30 mg/vial solution in a single use vial) at a dose of 3.4 mg/kg GSK2857916 as IV solution once every three weeks for a maximum of up to 32 cycles (1 cycle= 21 days). Frozen liquid was diluted with 0.9 percent saline.","id":"OG001","title":"Main Study: GSK2857916 3.4 mg/kg (Frozen Liquid)"},{"description":"Participants were administered lyophilized powder (100 mg/vial in a single use vial) at a dose of 3.4 mg/kg GSK2857916 given IV for a maximum of 35 cycles (1 cycle= 21 days). Lyophilized powder was reconstituted using water for injection.","id":"OG002","title":"Main Study: GSK2857916 3.4 mg/kg (Lyophilized)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Full PK Population. All the participants in the study were included in the analysis (95, 99 and 24 Participants), but only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).","reportingStatus":"POSTED","timeFrame":"Cycle 1 and Cycle 3: Pre-dose, EOI, 2 hours and 24 hours post SOI on Day 1, anytime on Day 4, and anytime on Day 8 to Day 15 (each cycle of 21 days)","title":"t1/2 of GSK2857916 Total Antibody Following IV Dose in Participants With RRMM","type":"SECONDARY","unitOfMeasure":"Hours"}